ExCellThera Inc. and its 100% subsidiary Cordex Biologics have obtained status 1 in the German NUB (Neue Untersuchungs- und Behandlungsmethoden) program for Zemcelpro (dorocubicel), also known as UM171 cell therapy.[1][2] This status recognizes the product's relevant and growing clinical evidence base.[1] It allows German hospitals to immediately request temporary additional reimbursement for its use while more comprehensive reimbursement methods are assessed.[1][2] As many as 220 hospitals in Germany have expressed interest in accessing Zemcelpro through the NUB mechanism in 2026.[1] Zemcelpro is indicated for adult patients with life-threatening blood cancers who have limited therapeutic options and need a hematopoietic stem cell (HSC) transplant.[2][5] The therapy combines ex vivo expanded CD34+ cells using the proprietary molecule UM171 with unmodified CD34- cells from the same cord blood unit.[5] The safety and effectiveness of Zemcelpro have not yet been finally confirmed by regulatory authorities such as the FDA, MHRA or Health Canada.[1]